Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Gerald J. Rowse"'
Publikováno v:
BMC Neurology, Vol 17, Iss 1, Pp 1-11 (2017)
Abstract Background Droxidopa, a prodrug of norepinephrine, was approved for treatment of neurogenic orthostatic hypotension (nOH) due to primary autonomic disorders based on 3 randomized double-blind studies. We performed safety and efficacy analyse
Externí odkaz:
https://doaj.org/article/389d485a1e0f48f69990f26dac5b9093
Publikováno v:
Journal of Parkinson's Disease. 6:751-759
Background Neurogenic orthostatic hypotension (nOH) is associated with insufficient norepinephrine release in response to postural change. Objective The objective of this study was to evaluate the long-term safety and durability of efficacy of the no
Publikováno v:
Journal of the American Society of Hypertension. 10(10):755-762
The long-term safety of droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Parkinson disease, pure autonomic failure, multiple system atrophy, or nondiabetic autonomic neuropathy was evaluated in a phase 3,
Publikováno v:
Clinical Neuropharmacology
OBJECTIVES: Droxidopa is a prodrug of norepinephrine indicated for the treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic neurogenic orthostatic hypotension caused
Publikováno v:
The American Journal of Cardiology.
The norepinephrine prodrug droxidopa improves symptoms of neurogenic orthostatic hypotension, a condition that is associated with diseases of neurogenic autonomic failure (e.g., Parkinson disease, multiple system atrophy, pure autonomic failure). The
Publikováno v:
BMC Neurology
BMC Neurology, Vol 17, Iss 1, Pp 1-11 (2017)
BMC Neurology, Vol 17, Iss 1, Pp 1-11 (2017)
Droxidopa, a prodrug of norepinephrine, was approved for treatment of neurogenic orthostatic hypotension (nOH) due to primary autonomic disorders based on 3 randomized double-blind studies. We performed safety and efficacy analyses of this pooled dat
Publikováno v:
BMC Neurology
Droxidopa is an orally active prodrug that significantly improved dizziness/lightheadedness measured using the Orthostatic Hypotension Symptom Assessment (OHSA) Item 1 in patients with neurogenic orthostatic hypotension (nOH) caused by primary autono
Publikováno v:
International Journal of Cancer. 80:595-599
C57BL/6 mice transgenic for human MUC1 (MUC1.Tg) have been developed to investigate the autoimmune consequences of producing MUC1 tumor immunity in an animal that expresses MUC1 as a self-protein on normal ductal epithelia. Previous work showed that
Autor:
Richard M. Tempero, Michelle L. VanLith, Keita Morikane, Gerald J. Rowse, Sandra J. Gendler, Michael A. Hollingsworth
Publikováno v:
The Journal of Immunology. 161:5500-5506
A C57BL/6 mouse transgenic for human MUC1 (MUC1.Tg) was developed to evaluate MUC1-specific tumor immunity in an animal that expresses MUC1 as a normal self protein. Previous studies showed that MUC1.Tg mice, challenged with syngeneic tumors expressi
Publikováno v:
Journal of the American Society of Hypertension. 9:e58
which is a nonabsorbed potassium (K)-binder, reduced serum K (s-K) and HK recurrence in CKD patients with HK on RAAS inhibitors (OPAL-HK). The purpose of this OPAL-HK analysis was to determine the fall in s-K with patiromer, and following randomized